FOXO4-DRI is a synthetic peptide designed to block the binding of the FOXO4 protein to p53 and push senescent (aged, non-dividing) cells to die. It has been studied only in cells and animals and is not approved for human use.
Powder vials are usually labeled 10 mg.
Water and syringe-unit charts by vial size: 10 mg
Here is the math for a 10 mg vial mixed with 2 mL of bacteriostatic water, drawing 1 mg with a U-100 insulin syringe (1 mL = 100 units).
10 mg ÷ 2 mL = 5 mg/mL1 mg ÷ 5 mg/mL = 0.2 mL0.2 mL × 100 = 20 units| Amount | Volume | U-100 syringe |
|---|---|---|
| 500 mcg | 0.1 mL | 10 units |
| 1 mg | 0.2 mL | 20 units |
| 2 mg | 0.4 mL | 40 units |
Adding more water doesn't change how much FOXO4-DRI is in the vial. It only spreads it over more liquid, so each draw is bigger and easier to read.
| Water added | Concentration | Volume | U-100 syringe |
|---|---|---|---|
| 1 mL | 10 mg/mL | 0.1 mL | 10 units |
| 2 mL | 5 mg/mL | 0.2 mL | 20 units |
| 3 mL | 3.33 mg/mL | 0.3 mL | 30 units |
| 5 mL | 2 mg/mL | 0.5 mL | 50 units |
For any other vial size or amount, the free peptide reconstitution calculator works backwards from the amount you want and suggests a water volume that lands on a clean syringe mark.
Nothing from trials. The original 2017 Cell paper showed that in mice, the peptide cleared senescent cells and reduced chemotherapy toxicity, and in aged mice it improved fitness, fur and kidney function. We could not find any published human study.
We could not find a published human half-life for this compound. Figures quoted online usually come from animal or cell studies, so we do not list one here.